cardiovascular outcomes

heart cardiovascular check up stethescope

Biotech

NewAmsterdam drug cuts cholesterol, but by less than expected

NewAmsterdam’s drug reduced cholesterol by 41% at Week 52, confirming the therapy’s efficacy but falling outside of the mark hit in phase 2.

Annalee Armstrong Jul 29, 2024 8:00am

Photo of a donkey saddled with bags with Nepali mountains in the background

Novartis bets $60M upfront on Ionis' next-gen cardiovascular med

Aug 3, 2023 11:15am